Venkatraman E Seshan

List of Publications by Year
in descending order

48 papers	3,347 citations	279798 23 h-index	254184 43 g-index
50 all docs	50 docs citations	50 times ranked	7891 citing authors

#	Article	IF	Citations
1	Clinical and Genomic Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS) Tj ETQq1 1 0.784314 rgBT /Overlo[Diseases, 2022, 75, e774-e782.	5.8	5
2	Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. Blood Cancer Journal, 2022, 12, 29.	6.2	1
3	Phase I study of intravesical anti-CD40 agonist antibody 2141-V11 for non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin (BCG) therapy.. Journal of Clinical Oncology, 2022, 40, TPS4616-TPS4616.	1.6	1
4	Testing tumors from different anatomic sites for clonal relatedness using somatic mutation data. Biometrics, 2021, 77, 283-292.	1.4	2
5	The association between tumor mutational burden and prognosis is dependent on treatment context. Nature Genetics, 2021, 53, 11-15.	21.4	139
6	Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nature Communications, 2021, 12, 729.	12.8	212
7	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Genome Medicine, 2021, 13, 96.	8.2	26
8	Response Rates to Anti–PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase. JAMA Oncology, 2021, 7, 739.	7.1	125
9	Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. Blood Cancer Journal, 2021, 11, 113.	6.2	35
10	Validity of a method for identifying disease subtypes that are etiologically heterogeneous. Statistical Methods in Medical Research, 2021, 30, 2045-2056.	1.5	1
11	Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer Journal, 2020, 10, 74.	6.2	81
12	Pan-cancer identification of clinically relevant genomic subtypes using outcome-weighted integrative clustering. Genome Medicine, 2020, 12, 110.	8.2	22
13	Positron-emission tomography–based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. European Journal of Cancer, 2020, 126, 78-90.	2.8	21
14	Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL).. Journal of Clinical Oncology, 2020, 38, e20018-e20018.	1.6	5
15	Evaluating the association between clonal hematopoiesis and germline pathogenic and likely pathogenic variants in cancer predisposition genes.. Journal of Clinical Oncology, 2020, 38, 1535-1535.	1.6	0
16	Characterization of patients with multiple primary tumors.. Journal of Clinical Oncology, 2020, 38, 1502-1502.	1.6	2
17	An EM algorithm to improve the estimation of the probability of clonal relatedness of pairs of tumors in cancer patients. BMC Bioinformatics, 2019, 20, 555.	2.6	2
18	Testing clonal relatedness of two tumors from the same patient based on their mutational profiles: update of the <i>Clonality</i> R package. Bioinformatics, 2019, 35, 4776-4778.	4.1	4

#	Article	IF	Citations
19	Identification of prognostic molecular biomarkers in 157 HPVâ€positive and HPVâ€negative squamous cell carcinomas of the oropharynx. International Journal of Cancer, 2019, 145, 3152-3162.	5.1	48
20	Vemurafenib Redifferentiation of *BRAF* Mutant, RAI-Refractory Thyroid Cancers. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1417-1428.	3.6	165
21	Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity. JCI Insight, 2019, 4, .	5.0	17
22	Validation of broad panel clinical sequencing-based genomic risk stratification in patients with advanced lung adenocarcinomas.. Journal of Clinical Oncology, 2019, 37, 9113-9113.	1.6	0
23	RE: â€œA MULTINOMIAL REGRESSION APPROACH TO MODEL OUTCOME HETEROGENEITYâ€. American Journal of Epidemiology, 2018, 187, 1129-1130.	3.4	2
24	Estimating the Probability of Clonal Relatedness of Pairs of Tumors in Cancer Patients. Biometrics, 2018, 74, 321-330.	1.4	8
25	Contralateral breast cancers: Independent cancers or metastases?. International Journal of Cancer, 2018, 142, 347-356.	5.1	37
26	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. Clinical Cancer Research, 2018, 24, 1965-1973.	7.0	85
27	NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12034-12039.	7.1	41
28	HSP90-incorporating chaperome networks as biosensor for disease-related pathways in patient-specific midbrain dopamine neurons. Nature Communications, 2018, 9, 4345.	12.8	40
29	Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nature Biotechnology, 2018, 36, 847-856.	17.5	564
30	BET Inhibition-Induced GSK3Î² Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors. Cell Reports, 2018, 24, 2155-2166.	6.4	31
31	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. Blood Cancer Journal, 2018, 8, 60.	6.2	25
32	Prognostic relevance of tumor sequencing in metastatic lung adenocarcinomas.. Journal of Clinical Oncology, 2018, 36, 9049-9049.	1.6	0
33	Defining Cancer Subtypes With Distinctive Etiologic Profiles: An Application to the Epidemiology of Melanoma. Journal of the American Statistical Association, 2017, 112, 54-63.	3.1	7
34	Mitochondrial DNA copy number variation across human cancers. ELife, 2016, 5, .	6.0	384
35	Asynchronous fate decisions by single cells collectively ensure consistent lineage composition in the mouse blastocyst. Nature Communications, 2016, 7, 13463.	12.8	122
36	Clonal relationships between lobular carcinoma in situ and other breast malignancies. Breast Cancer Research, 2016, 18, 66.	5.0	32

#	Article	IF	Citations
37	TNF is a key cytokine mediating neutrophil cytotoxic activity in breast cancer patients. Npj Breast Cancer, 2016, 2, 16009.	5.2	26
38	FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Research, 2016, 44, e131-e131.	14.5	809
39	Benchmark of Progression Free Survival for Multiple Lines of Therapy in Follicular Lymphoma Treated in the Rituximab Era. Blood, 2016, 128, 2955-2955.	1.4	4
40	Understanding the genomic underpinnings of metastatic chromophobe renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, 513-513.	1.6	1
41	Outcomes of Follicular Lymphoma Patients By Dynamic FLIPI at Diagnosis and Initial Treatment in the Post-Rituximab Era. Blood, 2016, 128, 4119-4119.	1.4	0
42	Dual Inhibition of Histone Deacetylases and Phosphoinositide 3-Kinase Enhances Therapeutic Activity Against B Cell Lymphoma. Blood, 2016, 128, 293-293.	1.4	0
43	Identifying Etiologically Distinct Sub‐Types of Cancer: A Demonstration Project Involving Breast Cancer. Cancer Medicine, 2015, 4, 1432-1439.	2.8	15
44	The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling. Nature Cell Biology, 2015, 17, 81-94.	10.3	97
45	Distinctive Genomic Alterations in Testicular Diffuse Large B Cell Lymphoma. Blood, 2015, 126, 3655-3655.	1.4	1
46	Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy. Journal of Experimental Medicine, 2014, 211, 1379-1391.	8.5	32
47	Gene-expression profiling to demonstrate select neutrophils from breast cancer patients versus healthy women as cytotoxic against breast cancer cells via novel chemokine-mediated mechanisms.. Journal of Clinical Oncology, 2014, 32, 11086-11086.	1.6	0
48	Comparing ROC curves derived from regression models. Statistics in Medicine, 2013, 32, 1483-1493.	1.6	62